New Options for the treatment of Paget's disease of the vulva;Neue optionen bei der therapie des morbus Paget der vulva

Geburtshilfe und Frauenheilkunde

Volumn 66, Issue 11, 2006, Pages 1081-1086

  Luyten, Alexander ^a   Brummer, O ^b   Kuhnle H ^c   Kreipe, H H ^c   Reinecke Luthge A ^d   Petry, K U ^a  

^a Klinikum der Stadt Wolfsburg   (Germany)

^b ASKLEPIOS KLINIK ALTONA   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Klinikum der Stadt Wolfsburg   (Germany)

Author keywords

Her 2 neu; Imiquimod; Paget's disease; Therapy; Trastuzumab

Indexed keywords

IMIQUIMOD;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; PAGET SKIN DISEASE; RECURRENT CANCER; REVIEW; X RAY;

EID: 33846931336     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924608     Document Type: Review

References (27)

1. Fanning J, Lambert HC, Hale TM, Morris PC, Schuerch C. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Am J Obstet Gynecol 1999; 180 (1 Pt 1): 24-27
2. Kürzl RG. Paget's disease. Semin Dermatol 1996; 15: 60-66
3. Kürzl R. Die Vulva als "l'origine des plaintes". Geburtsh Frauenheilk 2005; 65: 667-668
4. Tebes S, Cardosi R, Hoffman M. Paget's disease of the vulva. Am J Obstet Gynecol 2002; 187: 281-283
5. MacLean AB, Makwana M, Ellis PE, Cunnington F. The management of Paget's disease of the vulva. J Obstet Gynaecol 2004; 24: 124-128
6. Stanley MA. The imidazoquinolines - mechanism of action and therapeutic potential in HPV-associated disease. Papillomavirus Report 2005; 16: 141-146
7. Cox JT, Petry KU, Rylander E, Roy M. Using imiquimod for genital warts in female patients. J Womens Health (Larchmt.) 2004; 13: 265-271
8. Berman B, Spencer J, Villa A, Poochareon V, Elgart G. Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. Clin Exp Dermatol 2003; 28: 36-38
9. Qian Z, Zeitoun NC, Shieh S, Helm T, Oseroff AR. Successful treatment of extramammary Paget's disease with imiquimod. J Drugs Dermatol 2003; 2: 73-76
10. Wang LC, Blanchard A, Judge DE, Lorincz AA, Medenica MM, Busbey S. Successful treatment of recurrent extramammary Paget's disease of the vulva with topical imiquimod 5% cream. J Am Acad Dermatol 2003; 49: 769-772
11. Zampogna JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002; 47: 5229-5235
12. Kohler S, Rouse RV, Smoller BR. The differential diagnosis of pagetoid cells in the epidermis. Mod Pathol 1998; 11: 79-92
13. Wilkinson EJ, Brown HM. Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 2002; 33: 549-554
14. Nowak MA, Guerriere-Kovach P, Pathan A, Campbell TE, Deppisch LM. Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Arch Pathol Lab Med 1998; 122: 1077-1081
15. Goldblum JR, Hart WR. Vulvar Paget's disease: a clinicopathologic and immunohistochemical study of 19 cases. Am J Surg Pathol 1997; 21: 1178-1187
16. Goldblum JR, Hart WR. Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 1998; 22: 170-179
17. Ohnishi T, Watanabe S. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget's disease. Br J Dermatol 2000; 142: 243-247
18. Lerner LB, Andrews SJ, Gonzalez JL, Heaney JA, Currie JL. Vulvar metastases secondary to transitional cell carcinoma of the bladder. A case report. J Reprod Med 1999; 44: 729-732
19. Malik SM, Wilkinson EJ. Pseudo-Paget's disease of the vulva: A case report. J Lower Gen Tract Dis 1999; 3: 201-203
20. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200
21. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121: 1205-1209
22. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-1276
23. Haerslev T, Krag JG. Expression of cytokeratine and erbB-2 oncoprotein in Paget's disease of the nipple. An immunehistochemical study. APMIS 1992; 100: 1041-1047
24. Brummer O, Stegner HE, Bohmer G, Kuhnle H, Petry KU. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 2004; 95: 336-340
25. Curtin JP, Rubin SC, Jones WB, Hoskins WJ, Lewis JL Jr. Paget's disease of the vulva. Gynecol Oncol 1990; 39: 374-377
26. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 2003; 149: 53-56
27. Villa AM, Berman B. Immunomodulators for skin cancer. J Drugs Dermatol 2004; 3: 533-539